JUICE Pharma Worldwide was in Chicago to report on the proceedings of the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. Medical Director Florian Brey, MD, and the JUICE team share the latest developments and research advances in cancer treatment.
Florian discusses the many barriers and some surprising emerging developments in treating brain cancer:
“What is the best way to treat brain cancer? At ASCO, an education session on emerging topics in cellular and immunotherapies for CNS tumors shed some light on the status quo in both pediatric and adult patient populations. Many of the challenges to overcome are, of course, intrinsic to the target tissue because the brain is so different from other tissues in the body. For instance, the blood-brain barrier can be difficult to permeate for drugs. On the other hand, it can become leaky around tumors and thereby impaired in its physiologic role. Or the physiology of antigen presentation and immune response in the brain, which is very distinct from other tissues and other compartments in the body.
Some of the data presented compared and contrasted various treatments, including dendritic cell vaccines, adoptive cell transfer, and antigen targeting with peptides, and like in other areas of oncology, many signs point toward combination therapies.”